Microspheres and nanoparticles used in ocular delivery systems

被引:0
|
作者
Institute of Pharmaceutical Technology, Biocenter, Johann Wolfgang Goethe University, Marie-Curie-Strasse 9, D-60439, Frankfurt am Main, Germany [1 ]
机构
来源
ADV. DRUG DELIV. REV. | / 1卷 / 61-73期
关键词
Colloids - Composition effects - Diseases - Drug products - Drug therapy - Ophthalmology - Particles (particulate matter) - Solubility - Suspensions (fluids) - Vision;
D O I
暂无
中图分类号
学科分类号
摘要
Microparticles and nanoparticles are colloidal drug carriers in the micro- and submicron range. These systems were developed to overcome solubility problems of poorly soluble drugs as well as for long acting injectable depot formulations and specific drug targeting options. These carriers were also evaluated for ophthalmic drug delivery purposes over the past 15 years. The main objective for these systems was to improve the classical aqueous eye drop formulations which have major disadvantages like a rapid elimination of the drugs from the precorneal area. Consequently, colloidal carrier suspensions were designed to combine ophthalmic prolonged action with the ease of the application of liquid eye drops. The review summarizes the present manufacturing methods and the materials used for these delivery systems with respect to ophthalmic purposes. The distribution and penetration pathways of the particulate delivery systems are also described. The applications of drug-loaded particles are presented with focus on ophthalmic diseases like glaucoma, inflammations or infections of the eye. Accordingly, particulate carriers outlined in the review include systems loaded with pilocarpine, beta-blockers, hydrocortisone, amikacin, and miscellaneous drugs. Finally, the biodegradation and toxicity of the carrier materials under evaluation are reviewed.
引用
收藏
相关论文
共 50 条
  • [31] Solid lipid nanoparticles for ocular drug delivery
    Seyfoddin, Ali
    Shaw, John
    Al-Kassas, Raida
    DRUG DELIVERY, 2010, 17 (07) : 467 - 489
  • [32] Block Copolypeptide Nanoparticles for the Delivery of Ocular Therapeutics
    Stukenkemper, Timo
    Dose, Anica
    Caballo Gonzalez, Maria
    Groenen, Alexander J. J.
    Hehir, Sarah
    Andres-Guerrero, Vanessa
    Herrero Vanrell, Rocio
    Cameron, Neil R.
    MACROMOLECULAR BIOSCIENCE, 2015, 15 (01) : 138 - 145
  • [33] New nanoparticles for topical ocular delivery of erythropoietin
    Silva, Beatriz
    Marto, Joana
    Braz, Berta Sao
    Delgado, Esmeralda
    Almeida, Antonio Jose
    Goncalves, Lidia
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2020, 576
  • [34] Alginate nanoparticles as ocular drug delivery carriers
    Kianersi, Sogol
    Solouk, Atefeh
    Saber-Samandari, Saeed
    Keshel, Saeed Heidari
    Pasbakhsh, Pooria
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2021, 66
  • [35] Advances in ocular drug delivery systems
    Kang-Mieler, Jennifer J.
    Rudeen, Kayla M.
    Liu, Wenqiang
    Mieler, William F.
    EYE, 2020, 34 (08) : 1371 - 1379
  • [36] Advances in Ocular Drug Delivery Systems
    Silva-Cunha, Armando
    PHARMACEUTICS, 2021, 13 (09)
  • [37] OCULAR DRUG DELIVERY SYSTEMS: A REVIEW
    Macovei, Laura
    Gheorghe, Alina
    Schmitzer, Speranta
    Burcea, Marian
    Morosanu, Matei
    FARMACIA, 2021, 69 (06) : 1018 - 1031
  • [38] Ocular delivery systems of pefloxacin mesylate
    Bharath, S
    Hiremath, SRR
    PHARMAZIE, 1999, 54 (01): : 55 - 58
  • [39] Ocular drug delivery systems:An overview
    Ashaben Patel
    Kishore Cholkar
    Vibhuti Agrahari
    Ashim K Mitra
    World Journal of Pharmacology, 2013, (02) : 47 - 64
  • [40] Advances in ocular drug delivery systems
    Jennifer J. Kang-Mieler
    Kayla M. Rudeen
    Wenqiang Liu
    William F. Mieler
    Eye, 2020, 34 : 1371 - 1379